InKine Pharmaceutical Company, Inc. (INKP) Announces Positive Phase 3 Study Results Of Next Generation Purgative Product - INKP-102 
10/19/2005 5:12:47 PM

BLUE BELL, Pa.--(BUSINESS WIRE)--Feb. 22, 2005--InKine Pharmaceutical Company, Inc. (Nasdaq:INKP) today announced positive results of the Company's multicenter, Phase 3 study of its next generation sodium phosphate tablet, INKP-102. The recently completed, randomized, investigator blinded non-inferiority Phase 3 study included 706 adults who underwent colonoscopy. Patients received either 32 tablets ("reduced-dose") or 40 tablets ("comparator dose") of INKP-102 or the FDA-approved dose of 40 Visicol(R) tablets. Both of the INKP-102 arms utilized a dosing schedule that was of shorter duration, more convenient, and less complicated than the Visicol(R) dosing regimen. Approximately 25% of patients in the study were at least 65 years old and the study population included slightly more women than men and included all major U.S. ethnic groups.